Nonlethal Delayed Adverse Events
| Adverse Event (No. of Patients) . | Months From First Cladribine Therapy . |
|---|---|
| Infections | |
| Herpes zoster, dermatomal (7) | 10, 18, 20, 24, 41, 42, 69 |
| Hepatitis C (2) | 31, 51 |
| Mycobacterium tuberculosis (1) | 21 |
| Mycobacterium chelonei (1) | 38 |
| Cardiac or cerebrovascular | |
| Myocardial infarction (1) | 43 |
| Stroke (1) | 53 |
| Pulmonary | |
| Pneumonia, etiology undetermined (2) | 24, 52 |
| Interstitial lung disease (1) | 44 |
| Pulmonary embolism (1) | 66 |
| Neurological | |
| Peripheral neuropathy (2) | 9, 25 |
| Transverse myelitis (1) | 54 |
| Miscellaneous | |
| Thyrotoxicosis (2) | 17, 54 |
| Psoriatic arthropathy (1) | 34 |
| Polymyalgia rheumatica (1) | 36 |
| Adverse Event (No. of Patients) . | Months From First Cladribine Therapy . |
|---|---|
| Infections | |
| Herpes zoster, dermatomal (7) | 10, 18, 20, 24, 41, 42, 69 |
| Hepatitis C (2) | 31, 51 |
| Mycobacterium tuberculosis (1) | 21 |
| Mycobacterium chelonei (1) | 38 |
| Cardiac or cerebrovascular | |
| Myocardial infarction (1) | 43 |
| Stroke (1) | 53 |
| Pulmonary | |
| Pneumonia, etiology undetermined (2) | 24, 52 |
| Interstitial lung disease (1) | 44 |
| Pulmonary embolism (1) | 66 |
| Neurological | |
| Peripheral neuropathy (2) | 9, 25 |
| Transverse myelitis (1) | 54 |
| Miscellaneous | |
| Thyrotoxicosis (2) | 17, 54 |
| Psoriatic arthropathy (1) | 34 |
| Polymyalgia rheumatica (1) | 36 |